FISH was performed on bone marrow or blood samples that had been cultured for cytogenetic investigations and then stored for 0-16 years at −18°C in methanol:acetic acid fixative (3:1). The hybridization technique was as previously described by Andreasson et al. 5 The following probes were used: for ETV6, the YAC 964c10 and the 5′ ETV6 cosmid c179A6 (kindly provided by Dr P Marynen, Leuven, Belgium), and for ABL, the YAC 147e10 (kindly provided by CEPH, Paris, France). A whole chromosome painting probe for chromosome 9 and a partial chromosome painting probe for the short arm of chromosome 12 were used for chromosome identification. For each sample, at least 20 metaphases (ranging from 20 to 30) were analyzed.
None of the 67 CMD investigated displayed an ETV6/ABL fusion, suggesting that this chimeric gene is quite rare in CMD. One may argue, however, that metaphase FISH is not the optimal method to identify this abnormality because it may escape detection if the neoplastic cells do not divide in vitro. Obviously, expression analyses would have been preferable, but lack of RNA from most of the cases included in the present series precluded the use of RT-PCR. This notwithstanding, considering that the first ETV6/ABL fusion in a CML was detected by FISH and that we followed the same FISH protocol, 5 we believe that the present results are representative. One reason for the apparent rarity of ETV6/ABL may be its complex origin, ie at least three chromosome breaks are necessary in order to generate a functional fusion because of the chromosomal orientation of these two genes. 5 This explanation is of course only valid if one adheres to the view that breakage and reunion underlying translocations are stochastic events, which is indirectly supported by the fact that other neoplasia-associated rearrangements requiring more than two breaks, such as t(10;11) in AML 7 and t(21;22) in Ewing sarcoma, 8 are also infrequent. Furthermore, Janssen et al 9 using RT-PCR, ascertained the incidence of ETV6/ABL in 216 patients with ALL without detecting a single case with this transcript, again emphasizing that this abnormality is indeed rare. Table 2 it appears that the only significant (? Student's t-test based on six leukemic samples and four normal samples) difference was found after exposure to +42°C and only for marrow CFU-GM (17 vs 35%). No difference was found for blood CFU-GM and for marrow and blood LTCIC. From Table 3 it appears that a significant difference was found in two of 10 LTCIC experiments and in one of 10 CFU-GM experiments. There is a reasonable doubt that the observed differences could be due to chance. I understand that these experiments are difficult, expensive and time-consuming and I acknowledge that interesting data may be worth reporting even if they are still inconclusive. Incidentally, many reviewers would not share my opinion and would suggest rejection of papers unless they are conclusive. A reasonable compromise would be to acknowledge that the evidence is scant, if any, in the discussion, and to alter the title accordingly. However, I would like to profit by this study to make a more general case of the methods that are used to compare normal with leukemic, and of the underlying logic. In this study, as in many other studies, normal progenitors are identified, enumerated and tested based on assays that were developed specifically to identify and enumerate human normal progenitors, either CFU-GM or LTCIC. That makes sense. Leukemic progenitors were defined, identified, enumerated and tested based on the same assays. That makes less sense, because it is based on the assumption that 'leukemic' CFU-GM and LTCIC are the biologic counter-party of normal CFU-
Acknowledgements

Response to Michele Baccarani
TO THE EDITOR
Dr Baccarani wonders whether the data presented in our paper 'Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia' are firm enough to justify our statement that bcr-abl-positive progenitors are more sensitive to hyperthermic treatment than control cells. First, in contrast to what Dr Baccarani states, the differences between control and hyperthermia-treated samples as presented in Table 2 are significant not only for marrow CFU-GM at 42°C, but also at the LTC-IC level both in marrow and in peripheral blood. It has to be admitted that unfortunately details of the table can be misinterpreted easily, since due to an error in the superscripts an 'h' in the LTC-IC column, which stood for significance, has been replaced by a meaningless '9'. Since, in addition, similar trends are seen in bone marrow at 43°C both at the CFU-GM and especially on the LTC-IC level, the only exception in the six evaluable comparisons concerns peripheral blood at 42°C at the CFU-GM level. The results of these clonogenic assays confirm the molecular analysis: the hyperthermia-induced shifts in relative numbers of bcr-abl-positive and -negative colonies as shown in Table  4 are present both at the CFU-GM and the LTC-IC level and where indicated are significant by the objective methods presented. It should be emphasized, however, that these shifts occur almost exclusively in those cases where the control samples already contain bcr-abl-negative colonies: in only one out of 11 cases where in control samples all colonies were bcr-abl positive, a bcr-abl-negative colony was observed. When considering the total number of cases in which indeed a purging effect was found, it should thus be kept in mind that of a total number of 29 available comparisons only in 18 cases did the control sample contain a mixture of bcr-abl-positive and -negative colonies. It is in these samples that a relative increase of bcr-abl-negative colonies Correspondence: GJ Ossenkoppele Received 10 March 1998; accepted 12 March 1998 GM and LTCIC and that the organization of leukemic hemopoiesis is identical to the organization of normal hemopoiesis. In other words, are CFU-GM or LTCIC or whatever other progenitors, as they are defined using assays that were developed for normal cells, relevant to leukemia? In CML the number of 'leukemic' LTCIC is small and their ability to generate 'leukemic' CFU-GM is decreased, but Ph + cells have no problems in outgrowing normal cells. In acute leukemia we are not able to identify 'leukemic' LTCIC, but leukemia grows as well. The progression of CML towards blastic phase can be decided and accomplished by cells that were never able to grow in a CFU-GM or a LTCIC assay. Do you think that Leukemia might open a debate on these points? It could be interesting.
M Baccarani
Cattedra di Ematologia Policlinico Universitario Piazza S Maria della Misericordia I-33100 Udine, Italy was found in 15 out of 17 cases, be it that only in part of the individual cases was statistical significance reached. In our opinion this gives additional support for the conclusion that hyperthermia has a purging effect in CML with the restriction that such is seen almost exclusively in mixed colony samples. We certainly agree that a larger number of samples would strengthen our conclusions, but as pointed out in our paper, we aim at obtaining fresh chronic phase CML samples with mixtures of bcr-abl-positive and -negative progenitors and such samples are relatively rare, as was also acknowledged by Dr Baccarani.
In a second comment, the point is raised whether CFU-GM and LTC-IC assays are relevant to investigate leukemia. Indeed it should be kept in mind that both the CFU-GM and the LTC-IC assay are artificial in vitro assays with the latter having the additional complication that leukemic cells might propagate less efficiently in LTC-IC culture. Dr Baccarani suggests that the number of 'leukemic' LTC-IC as well as CFU-GM output in CML is too small to account for rapid overgrowth of normal cells by Ph + cells. This is still a matter of debate. Our results indicate that the frequency of LTC-IC (number of LTCICs/CD34-positive cells) and the output (CFU-GM/LTC-IC) can be as high as in non-CML CD34 cells (Ref. 1, see for example also sample 1054 in Table 3 , in which the colonies evaluated for frequency and output determination are 100% bcr-abl positive, as shown in Table 4 ). An additional point raised by the authors concerns blast crises CML and acute myeloid leukemia, a disease which is in some aspects very comparable to blast crises CML. These cells have probably undergone differentiation and one might argue that in vitro stem cell assays might be less appropriate for evaluation of in vitro treatments. On the other hand and in contrast to Dr Baccarani's suggestion, it is our experience that LTC-ICs can be generated from acute myeloid leukemia, while in addition, using the NOD SCID mouse model, there is now support 2 for the hypothesis that leukemia-initiating cells in most cases are present in a phenotypically defined CD34-positive subpopulation (CD38 negative) that also harbors the normal stem cells. Lastly, we
